Sandra Mangsbo

Utbildning, examen och certifikat

Vetenskapliga publikationer

• Optimizing T cell responses of targeted peptide antigen delivery by modulating antigen processing through amino acid exchange. (2026) forfattare
• Blood Levels of Dendritic Cell Populations in Patients with Moderate to Severe Traumatic Brain Injury. (2025) forfattare
• Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement. (2025) forfattare
• Repeated positron emission tomography tracing neutrophil elastase in a porcine intensive-care sepsis model. (2025) forfattare
• A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T proliferation and anti-tumor immunity in mice. (2024) forfattare
• Correction: Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations. (2024) forfattare
• MALT1 inhibition suppresses antigen-specific T cell responses. (2024) forfattare
• Bridging responses to a human telomerase reverse transcriptase-based peptide cancer vaccine candidate in a mechanism-based model. (2024) forfattare
• Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer. (2023) forfattare
• Antibodies from serum and CSF of multiple sclerosis patients bind to oligodendroglial and neuronal cell-lines. (2023) forfattare
• Epitopes Displayed in a Cyclic Peptide Scaffold Bind SARS-COV-2 Antibodies. (2023) forfattare
• Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers. (2023) forfattare
• Whole protein or long peptides in therapeutic vaccination strategies, does it make a difference? (2023) forfattare
• Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination. (2022) forfattare
• Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection. (2022) forfattare
• Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials. (2022) forfattare
• Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab. (2022) forfattare
• Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time. (2022) forfattare
• Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology. (2022) forfattare
• Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines. (2022) forfattare
• Whole protein or long peptides in therapeutic vaccination strategies, does it make a difference? (2023) forfattare
• Abstract A137: The innate/adaptive immune response triggered in response to local immunotherapy of orthotopically growing bladder cancer tumors (2019) forfattare
• 842 A novel agonistic anti-CD40 targeting strategy with an affinity peptide binding feature for antigen cargo functionality: improving peptide stability and T cell proliferation (2020) forfattare
• Tumor localized agonistic anti-CD40 therapy and beyond (2020) forfattare
• Selective FcγR engagement by human agonistic anti-CD40 antibodies (2016) forfattare
• Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer (2014) forfattare
• Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential (2021) forfattare
• Blood Levels of Dendritic Cell Populations in Patients with Moderate to Severe Traumatic Brain Injury (2025) forfattare
• Antibodies from serum and CSF of multiple sclerosis patients bind to oligodendroglial and neuronal cell-lines (2023) forfattare
• Abstract CT108: Phase I data from TENDU101, a first-in-human trial of a novel synthetic peptide conjugate cancer vaccine platform assessed in recurrent prostate cancer patients before salvage treatment (2024) forfattare
• Tim-3 and PD-1: Regulators of adaptive immunity in multiple sclerosis (2014) forfattare
• Abstract 1485: Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment (2016) forfattare
• A Hexon and Fiber-modified Adenovirus Expressing CD40L Improves the Antigen Presentation Capacity of Dendritic Cells (2014) forfattare
• CpG Therapy is Superior to BCG in an Orthotopic Bladder Cancer Model and Generates CD4+ T-cell Immunity (2008) forfattare
• Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation (2017) forfattare
• Bridging responses to a human telomerase reverse transcriptase-based peptide cancer vaccine candidate in a mechanism-based model (2024) forfattare
• Kick-starting the cancer-immunity cycle by targeting CD40 (2015) forfattare
• Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients (2017) forfattare
• Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment (2016) forfattare
• Abstract 501: Early immunological events in the periphery and the TME following a local immunostimulating instillation into the bladder in the MB49 orthotopic model (2019) forfattare

Författare och granskare på Skadekompassen

• Ont i höften Författare
• Metatarsalgi Författare
• EPTE - EPI Författare
• Mortons neurom Författare